BIOMARKERS OF CARDIOVASCULAR DISEASE

封面

如何引用文章

全文:

详细

Inflammation, cardiac remodeling, and fibrosis are potentially important pathways in the pathogenesis of cardiovascular diseases. Complications of atherosclerosis are one of the leading causes of death in the world. Effective prevention of cardiovascular disease by adequate control of major cardiovascular risk factors can provide substantial public health gains. However, detection and control of major cardiovascular risk factors continues to be a major challenge because of poor awareness of an individual's status. A solution to this problem is important for an early identification and appropriate correction of cardiovascular risk factors. Atherosclerotic plaque development is regarded as a chronic inflammatory process which involves interactions between lipids, immune cells and the artery wall. Numerous evidence suggests that inflammation plays an important role in all stages of the atherosclerotic process. The study of associations of inflammatory biomarkers has led to the idea that the panel of inflammatory biomarkers can identify people at high risk of developing atherosclerosis and cardiovascular diseases when anti-inflammatory treatment can prevent further unfavorable events. The most common forms of cardiovascular diseases are caused by atherosclerosis, the progressive thinning of blood vessels due to accumulation of lipids within the arterial wall. While many factors are known to influence the development and progression of atherosclerosis, circulating levels of cholesterol and lipoprotein complexes are the most important risk factors and mediators of atherosclerotic disease. Key regulators of lipid metabolism and/or the development of atherosclerosis have diagnostic, prognostic and therapeutic potential for cardiovascular diseases.

作者简介

S Scherbak

SPbSU; St. Petersburg City hospital №40

Email: kreml74@mail.ru
Department of postgraduate medical education, Faculty of Medicine St. Petersburg, Russia

D Lisovets

St. Petersburg City hospital №40

St. Petersburg, Russia

A Sarana

SPbSU; St. Petersburg City hospital №40

Department of postgraduate medical education, Faculty of Medicine St. Petersburg, Russia

T Kamilova

St. Petersburg City hospital №40

St. Petersburg, Russia

O Glotov

SPbSU; St. Petersburg City hospital №40

Department of postgraduate medical education, Faculty of Medicine St. Petersburg, Russia

A Anisenkova

St. Petersburg City hospital №40

St. Petersburg, Russia

S Apalko

St. Petersburg City hospital №40

St. Petersburg, Russia

S Urazov

St. Petersburg City hospital №40

St. Petersburg, Russia

参考

  1. Akpinar A, Ucler N, Erdogan U et al. Measuring serum matrix metalloproteinase-9 levels in peripheral blood after subarachnoid hemorrhage to predict cerebral vasospasm. Springerplus. 2016;5(1):1153. doi: 10.1186/s40064-016-2837-6.
  2. Al-Mufti F, Amuluru K, Smith B et al. Emerging markers of early brain injury and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. World Neurosurg. 2017;107:148-159. doi: 10.1016/j. wneu.2017.07.114.
  3. Altara R, Manca M, Hessel MH et al. CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study. J CardiovascTransl Res. 2016;9(4):302-314. doi: 10.1007/s12265-016-9703-3.
  4. Ammirati E, Moroni F, Magnoni M et al. Circulating CD14+ and CD-14highCD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. Atherosclerosis. 2016;255:171-178. doi: 10.1016/j.atherosclerosis.2016.10.004.
  5. Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2015;179(2):173-187. doi: 10.1111/cei.12477.
  6. Ammirati E, Moroni F, Norata GD et al. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015;2015:718329. doi: 10.1155/2015/718329.
  7. Ansari WM, Humphries SE, Naveed AK, et al. Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease. Postgrad Med J. 2017;93(1098):209-214. doi: 10.1136/postgradmedj-2016-134167.
  8. Bagheri R, Qasim AN, Mehta NN et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol. 2010;106(8):1118-1123. doi: 10.1016/j.amjcard.2010.06.028.
  9. Bai X.Y., Li S., Wang M., et al. Association of monocyte chemoattractant protein-1 (MCP-1)-2518A>G polymorphism with susceptibility to coronary artery disease: a meta-analysis. Ann. Hum. Genet. 2015;79(3):173-187. doi: 10.1111/ahg.12105.
  10. Bergmark BA, Udell JA, Morrow DA et al. Association of Fibroblast Growth Factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2018;3(6):473-480. doi: 10.1001/jama-cardio.2018.0653.
  11. Bettencourt P, Coimbra J, Rodrigues P et al. Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15. ESC Heart Fail. 2018 Aug 24. doi: 10.1002/ehf2.12301.
  12. Bielecka-Dabrowa A, Sakowicz A, Misztal M et al. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. Int J Cardiol. 2016;221:1073-1080. doi: 10.1016/j. ijcard.2016.07.150.
  13. Björkbacka H, Yao Mattisson I, Wigren M et al. Plasma stem cell factor levels are associated with risk of cardiovascular disease and death. J Intern Med. 2017;282(6):508-521. doi: 10.1111/joim.12675.
  14. Burchardt P, Rzezniczak J, Dudziak J et al. Evaluation of plasma PCSK9 concentrations, transcript of LDL, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients. Cardiol J. 2016;23(6):604-609. doi: 10.5603/CJ.a2016.0068.
  15. Cavusoglu E, Marmur JD, Hegde S et al. Relation of baseline plasma MMP-1 levels to long-term all-cause mortality in patients with known or suspected coronary artery disease referred for coronary angiography. Atherosclerosis. 2015;239(1):268-275. doi: 10.1016/j.atherosclero-sis.2015.01.003.
  16. Chen WJ, Rijzewijk LJ, van der Meer RW et al. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol. 2011;10:67. doi: 10.1186/1475-2840-10-67.
  17. Chen XL, Li Q, Huang WS et al. Serum YKL-40, a prognostic marker in patients with large-artery atherosclerotic stroke. Acta Neurol Scand. 2017;136(2):97-102. doi: 10.1111/ane.12688.
  18. Chi G, Januzzi JL, Korjian S et al. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017;44(4):457-465. doi: 10.1007/s11239-017-1552-7.
  19. Chiara TD, Argano C, Scaglione A. Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk. Acta Cardiol. 2015;70(1):33-40.
  20. Chou SH, Robertson CS; Participants in the International Multi-disciplinary Consensus Conference on the Multimodality Monitoring. Monitoring biomarkers of cellular injury and death in acute brain injury. Neurocrit. Care. 2014;21(Suppl. 2):S187-214. doi: 10.1007/s12028-014-0039-z.
  21. Clarke R, Valdes-Marquez E1, Hill M et al. Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open Heart. 2018;5(1):e000807. doi: 10.1136/openhrt-2018-000807.
  22. Cramer SC, Procaccio V, Americas G. GAIN International Study Investigators Correlation between genetic polymorphisms and stroke recovery: analysis of the GAIN Americas and GAIN International Studies. Eur J Neurol. 2012;19(5):718-724. doi: 10.1111/j.1468-1331.2011.03615.x.
  23. Cypen J, Ahmad T, Testani JM, DeVore AD. Novel biomarkers for the risk stratification of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2017;14(5):434-443. doi: 10.1007/s11897-017-0358-4.
  24. Cyrille NB, Villablanca PA, Ramakrishna H. Soluble urokinase plasminogen activation receptor--An emerging new biomarker of cardiovascular disease and critical illness. Ann Card Anaesth. 2016;19(2):214-216. doi: 10.4103/0971 -9784.179588.
  25. Davis FM, Rateri DL, Daugherty A. Abdominal aortic aneurysm: novel mechanisms and therapies. Curr Opin Cardiol. 2015;30(6):566-573. doi: 10.1097/HCO.0000000000000216.
  26. De Haan JJ, Haitjema S, den Ruijter HM et al. Growth Differentiation Factor 15 is associated with major amputation and mortality in patients with peripheral artery disease. J Am Heart Assoc. 2017;6(9).pii: e006225. doi: 10.1161/JAHA.117.006225.
  27. Defesche JC, Gidding SS, Harada-Shiba M et al. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/ nrdp.2017.93.
  28. Del Porto F, Proietta M, di Gioia C et al. FGF-23 levels in patients with critical carotid artery stenosis. Intern Emerg Med. 2015;10(4):437-444. doi: 10.1007/s11739-014-1183-3.
  29. Domouzoglou, E.M., Naka, K.K., Vlahos, et al. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol. 2015;309(6):H1029-1038. doi: 10.1152/ajp-heart.00527.2015.
  30. Du W, Piek A, Schouten EM et al. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018;8(15):4155-4169. doi: 10.7150/thno.26055.
  31. Duschek N, Stojakovic T, Ghai S et al. Ratio of apolipoprotein A-II/B improves risk prediction of postoperative survival after carotid endarterectomy. Stroke. 2015;46(6):1700-1703. doi: 10.1161/ STROKEAHA.115.009663.
  32. Eijsvogels TMH, Thompson PD, Franklin BA. The “Extreme Exercise Hypothesis”: recent findings and cardiovascular health implications. Curr Treat Options Cardiovasc Med. 2018;20(10):84. doi: 10.1007/ s11936-018-0674-3.
  33. Eilenberg W, Stojkovic S, Piechota-Polanczyk A et al. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro. Eur J Vasc Endovasc Surg. 2016;51(5):623-631. doi: 10.1016/j. ejvs.2016.01.009.
  34. Emiru T, Bershad EM, Zantek ND et al. Intracerebral hemorrhage: a review of coagulation function. Clin Appl Thromb Hemost. 2013;19(6):652-662. doi: 10.1177/1076029612454938.
  35. Falcâo F, de Oliveira FRA, da Silva MCFC, Sobral Filho DC. Carbohydrate antigen 125: a promising tool for risk stratification in heart diseases. Biomark Med. 2018;12(4):367-381. doi: 10.2217/bmm-2017-0452.
  36. Falkentoft AC, Rqrth R, Iversen K et al. MR-proADM as a prognostic marker in patients with ST-segment-elevation myocardial infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy. J Am Heart Assoc. 2018;7(11). pii: e008123. doi: 10.1161/JAHA.117.008123.
  37. Farzin L, Shamsipur M, Samandari L, Sheibani S. Recent advances in designing nanomaterial based biointerfaces for electrochemical biosensing cardiovascular biomarkers. J Pharm Biomed Anal. 2018;161:344-376. doi: 10.1016/j.jpba.2018.08.060.
  38. Fittipaldi S, Pini R, Pasquinelli G et al. High sensitivity C-reactive protein and vascular endothelial growth factor as indicators of carotid plaque vulnerability. J Cardiovasc Surg (Torino). 2016;57(6):861-871.
  39. Fukumitsu R, Takagi Y, Yoshida K, Miyamoto S. Endoglin (CD105) is a more appropriate marker than CD31 for detecting microvessels in carotid artery plaques. Surg Neurol Int. 2013;4:132. doi: 10.4103/2152-7806.119081.
  40. Furuhashi M, Ogura M, Matsumoto M et al. Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in re lation to cholesterol efflux from macrophages. Sci Rep. 2017;7(1):217. doi: 10.1038/s41598-017-00177-w.
  41. Gabrile SA, Antonangelo L, Capelozzi VR et al. Analysis of the acute systemic and tissue inflammatory response following carotid endarterectomy. Int Angiol. 2016;35(2):148-156.
  42. Getz GS, Krishack PA, Reardon CA. Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016;27(5):531-535. doi: 10.1097/ MOL.0000000000000331.
  43. Gluba-Brzozka A, Michalska-Kasiczak M, Franczyk B et al. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids Health Dis. 2016;15:22. doi: 10.1186/ s12944-016-0191-x.
  44. Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as a biomarker in cardiovascular disease. Biomark Med. 2014;8(1):133-140. doi: 10.2217/bmm.13.102.
  45. Gohar A, Gonçalves I, Vrijenhoek J et al. Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis. Int J Cardiol. 2017;241:430-436. doi: 10.1016/j.ijcard.2017.03.101.
  46. Goldberg A, Curtis CL, Kleim JA. Linking genes to neurological clinical practice: the genomic basis for neurorehabilitation. J Neurol Phys Ther. 2015;39(1):52-61. doi: 10.1097/NPT.0000000000000066.
  47. Gori AM, Giusti B, Piccardi B et al. Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis. J Cereb Blood Flow Metab. 2017;37(9):3253-3261. doi: 10.1177/0271678X17695572.
  48. Gottlieb SS, Harris K, Todd J et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clin Biochem. 2015;48(4-5):292-296. doi: 10.1016/j.clinbiochem.2014.12.012.
  49. Grande D, Leone M, Rizzo C et al. A multiparametric approach based on NT-proBNP, ST2, and Galectin3 for stratifying one year prognosis of chronic heart failure outpatients. J Cardiovasc Dev Dis. 2017;4(3). pii: E0009. doi: 10.3390/jcdd4030009.
  50. Gregersen I, Skjelland M, Holm S. et al. Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis. PLoS One. 2013;8(8):e72769. doi: 10.1371/journal.pone.0072769.
  51. Griessenauer CJ, Chua MH, Hanafy KA et al. Soluble Fms-like tyrosine kinase 1 (sFlt-1) and risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. World Neurosurg. 2017;108:84-89. doi: 10.1016/j.wneu.2017.08.128.
  52. Hassan M. STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Glob Cardiol Sci Pract. 2015;2015:6. doi: 10.5339/gcsp.2015.6.
  53. Herder C, de Las Heras Gala T, Carstensen-Kirberg M et al. Circulating levels of interleukin 1 -receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler Thromb Vasc Biol. 2017;37(6):1222-1227. doi: 10.1161/ATVBA-HA.117.309307.
  54. Holm Nielsen S, Tengryd C, Edsfeldt A et al. A biomarker of collagen type I degradation is associated with cardiovascular events and mortality in patients with atherosclerosis. J Intern Med. 2018 Aug 28. doi: 10.1111/joi m.12819.
  55. Hosseinkhani B, Kuypers S, van den Akker NMS et al. Extracellular vesicles work as a functional inflammatory mediator between vascular endothelial cells and immune cells. Front Immunol. 2018 Aug 6;9:1789. doi: 10.3389/fimmu.2018.01789.
  56. Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol. 2018;175(9):1377-1400. doi: 10.1111/bph.14155.
  57. Huxley RR, Lopez FL, MacLehose RF et al. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. PLoS One. 2013;8(3):e59052. doi: 10.1371/journal.pone.0059052,
  58. Igari K, Kudo T, Toyofuku T, Inoue Y. Relationship of inflammatory biomarkers with severity of peripheral arterial disease. Int J Vasc Med. 2016;2016:6015701. doi: 10.1155/2016/6015701.
  59. Itzecki M, Itzecka J, Przywara S et al. Effect of carotid endarterectomy on brain damage markers. Acta Neurol Scand. 2017;135(3):352-359. doi: 10.1111/a ne.12607.
  60. Jabati S, Fareed J, Liles J et al. Biomarkers ofinflammation, thrombogenesis, and collagen turnover in patients with atrial fibrillation. Clin Appl Thromb Hemost. 2018;24(5):718-723. doi: 10.1177/1076029618761006.
  61. Jaroslav P, Christian R, Stefan O, et al. Evaluation of serum biomarkers for patients at increased risk of stroke. Int J Vasc Med. 2012;2012:906954. doi: 10.1155/2012/906954.
  62. Jirak P, Mirna M, Wernly B et al. Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease (PAD). Minerva Med. 2018 Apr 12. doi: 10.23736/S0026-4806.18.05628-8.
  63. Jokerst JV1, Cauwenberghs N2, Kuznetsova T. et al. Circulating biomarkers to identify responders in cardiac cell therapy. Sci Rep. 2017;7(1):4419. doi: 10.1038/s41598-017-04801-7.
  64. Karabina S, Ninio E. Plasma PAFAH/PLA2G7 genetic variability, cardiovascular disease, and clinical trials. Enzymes. 2015;38:145-155. doi: 10.1016/bs.enz.2015.09.002.
  65. Kazmierczak E., Grajek S., Kowal J., et al. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. Eur. Rev. Med. Pharmacol. Sci. 2014;18(15):2169-2175.
  66. Khine HW, Teiber JF, Haley RW et al. Association of the serum my-eloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study. Atherosclerosis. 2017;263:156-162. doi: 10.1016/j.atherosclerosis.2017.06.007.
  67. Kido T, Kondo K, Kurata H et al. ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator. Lipids Health Dis. 2017;16(1):225. doi: 10.1186/s12944-017-0619-y.
  68. Kim ND, Luster AD. To B or not to B--that is the question for myocardial infarction. Nat Med. 2013;19(10):1208-1210. doi: 10.1038/nm.3367.
  69. Kothari H, Nguyen AT, Yang X et al. Association of D-dimer with plaque characteristics and plasma biomarkers of oxidation-specific epitopes in stable subjects with coronary artery disease. J Cardiovasc Transl Res. 2018;11 (3):221-229. doi: 10.1007/s12265-018-9790-4.
  70. Krishnan S, Huang J, Lee H. et al. Combined high-density lipoprotein proteomic and glycomic profiles in patients at risk for coronary artery disease. J Proteome Res. 2015;14(12):5109-5118. doi: 10.1021/acs. jproteome.5b00730.
  71. Ladouceur M, Baron S, Nivet-Antoine V et al. Role of myocardial collagen degradation and fibrosis in right ventricle dysfunction in transposition of the great arteries after atrial switch. Int J Cardiol. 2018;258:76-82. doi: 10.1016/j.ijcard.2018.01.100.
  72. LaRocca G, Aspelund T, Greve AM et al. Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study. Eur Heart J. 2017;38(46):3423-3430. doi: 10.1093/eurheartj/ ehx510.
  73. Lepedda AJ, Nieddu G, Zinellu E et al. Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker. Oxid Med Cell Longev. 2013;2013:385214. doi: 10.1155/2013/385214.
  74. Li J, Gu C, Li D et al. Effects of serum N-terminal pro B-type natriuretic peptide and D-dimer levels on patients with acute ischemic stroke. Pak J Med Sci. 2018;34(4):994-998. doi: 10.12669/pjms.344.15432.
  75. Li M, Wang S, Zhang Y, Ma S, Zhu P. Correlation between pigment epithelium-derived factor (PEDF) level and degree of coronary angiography and severity of coronary artery disease in a chinese population. Med Sci Monit. 2018;24:1751-1758. PMID: 29574467. PMCID: PMC5881452.
  76. Liberale L, Carbone F, Bertolotto M et al. Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis. Vascul Pharmacol. 2018;102:37-43. doi: 10.1016/j. vph.2017.12.066.
  77. Liebetrau C, Hoffmann J, Dörr O et al. Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ Res. 2015;116(5):867-875. doi: 10.1161/CIRCRESAHA.116.304653.
  78. Lin C, Tang X, Shi Z et al. Serum tumor necrosis factor a levels are associated with new ischemic brain lesions after carotid artery stenting. J Vasc Surg. 2018;68(3):771 -778. doi: 10.1016/j.jvs.2017.11.085.
  79. Lippi G, Schena F, Salvagno GL, Sanchis-Gomar F, Guidi GC. Serum copeptin and midregion proadrenomedullin (MR-proADM) after an ultramarathon. J Clin Lab Anal. 2015;29(1):15-20. doi: 10.1002/jcla.21720.
  80. Liu W, Liu Y, Jiang H et al. Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention. Inflammation.2013;36(5):1129-1135. doi: 10.1007/s10753-013-9647-6.
  81. Magnussen C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med. 2018;283(6):530-543. doi: 10.1111/joi m.12756.
  82. Mallamaci F, Leonardis D, Pizzini P et al. Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. J Hypertens. 2013;31(7):1424-1430; discussion 1430. doi: 10.1097/HJH.0b013e328360ddd5.
  83. Marino F, Tozzi M, Schembri L et al. Production of IL-8, VEGF and elastase by circulating and intraplaque neutrophils in patients with carotid atherosclerosis. PLoS One. 2015;10(4):e0124565. doi: 10.1371/ journal.pone.0124565.
  84. Matsuura, K. et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. J. clin. invest. 2009;119(8):2204-2217. doi: 10.1172/JCI37456.
  85. Maurovich-Horvat P, Kallianos K, Engel LC et al. Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers. Obesity (Silver Spring). 2015;23(6):1178-1184. doi: 10.1002/oby.21080.
  86. McCarthy CP, Januzzi JL Jr. Soluble ST2 in heart failure. Heart Fail Clin. 2018;14(1):41 -48. doi: 10.1016/j.hfc.2017.08.005.
  87. McFarland CP, Lind SE. Thrombin generation biomarkers decline with parenteral anticoagulation-an overlooked means of anticoagulation monitoring? Clin Appl Thromb Hemost. 2018;24(5):708-717. doi: 10.1177/1076029617746506.
  88. Memon AA, Sundquist K, PirouziFard M Identification of novel diagnostic biomarkers for deep venous thrombosis. Br J Haematol. 2018;181 (3):378-385. doi: 10.1111/bjh.15206.
  89. Michalska-Kasiczak M, Bielecka-Dabrowa A, von Haehling S et al. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Arch Med Sci. 2018;14(4):890-909. doi: 10.5114/aoms.2018.76279.
  90. Moreno JA, Ortega-Gomez A, Delbosc S, et al. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur. heart j. 2012;33(2):252-263. doi: 10.1093/eurheartj/ehr123.
  91. Morine KJ, Paruchuri V, Qiao X et al. Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis. Biomarkers. 2016;21(1):91-97. doi: 10.3109/1354750X.2015.1118539.
  92. Musialek P, Tracz W, Tekieli L et al. Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis. J Clin Neurol. 2013;9(3):165-175. doi: 10.3988/ jcn.2013.9.3.165.
  93. Myhre PL, Vaduganathan M, Claggett BL et al. Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial. JAMA Cardiol. 2018 Aug 22. doi: 10.1001/jamacardio.2018.2568.
  94. Naka KK, Bechlioullis A, Marini A et al. Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. J Clin Lipidol. 2018;12(2):338-347. doi: 10.1016/j. jacl.2017.12.004.
  95. Nolan N, Tee L, Vijayakumar S et al. Analytical performance validation of a coronary heart disease risk assessment multi-analyte proteomic test. Expert Opin Med Diagn. 2013;7(2):127-36. doi: 10.1517/17530059.2013.753055.
  96. Norata G., Ballantyne C., Catapano A. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur. Heart J. 2013;34(24):1783-1789. doi: 10.1093/eurheartj/eht088.
  97. Nowak C, Carlsson AC, Östgren CJ et al. Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia. 2018;61 (8):1748-1757. doi: 10.1007/s00125-018-4641 -z.
  98. Omer W, Naveed AK, Khan OJ, Khan DA. Role of cytokine gene score in risk prediction of premature coronary artery disease. Genet. Test Mol. Biomarkers. 2016;20(11):685-691. doi: 10.1089/gtmb.2016.0108
  99. Pascual-Figal DA, Lax A, Perez-Martinez MT. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29-35. doi: 10.1515/cclm-2015-0074.
  100. Pelisek J, Well G, Reeps C, et al. Neovascularization and angiogenic factors in advanced human carotidartery stenosis. Circ J. 2012;76(5):1274-1282.
  101. Peller M, Lodzinski P, Ozieranski K et al. The influence of the atrial fibrillation episode duration on the endothelial function in patients treated with pulmonary veins isolation. Adv Clin Exp Med. 2017;26(1):109-113. doi: 10.17219/acem/66995.
  102. Persic V, Bastiancic AL, Rosovic I et al. Correlation between immunological-inflammatory markers and endothelial disfunction in the early stage of coronary heart disease. Med Hypotheses. 2018;115:72-76. doi: 10.1016/j.mehy.2018.04.001.
  103. Pfeiler S, Winkels H, Kelm M, Gerdes N. IL-1 family cytokines in cardiovascular disease. Cytokine. 2017 Nov 30. pii: S1043-4666(17)30351-4. doi: 10.1016/j.cyto.2017.11.009.
  104. Planavila A, Fernandez-Solà J, Villarroya F. Cardiokines as modulators of stress-induced cardiac disorders. Adv Protein Chem Struct Biol. 2017;108:227-256. doi: 10.1016/bs.apcsb.2017.01.002.
  105. Poredos P, Spirkoska A, Lezaic L, et al. Patients with an inflamed atherosclerotic plaque have increased levels of circulating inflammatory markers. J Atheroscler Thromb. 2017;24(1):39-46. doi: 10.5551/jat.34884.
  106. Rao VH, Kansal V, Stoupa S, Agrawal DK. MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep. 2014;2(2):e00224. doi: 10.1002/phy2.224.
  107. Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243(2):383-388. doi: 10.1016/j.atherosclerosis.2015.10.003.
  108. Rotllan N, Price N, Pati P et al. microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis. 2016;246:352-360. doi: 10.1016/j.atherosclerosis.2016.01.025.
  109. Roy-O'Reilly M, Zhu L, Atadja L et al. Soluble CD163 in intracerebral hemorrhage: biomarker for perihematomal edema. Ann Clin Transl Neurol. 2017;4(11):793-800. doi: 10.1002/acn3.485.
  110. Samuelson Bannow BT, Konkle BA. Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review. Thromb Res. 2018;163:138-145. doi: 10.1016/j. thromres.2018.01.037.
  111. Santema BT, Kloosterman M, Van Gelder IC et al. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J. 2018 Aug 22. doi: 10.1093/eurheartj/ehy421.
  112. Sarchielli P, Nardi K, Chiasserini D et al. Immunological profile of silent brain infarction and lacunar stroke. PLoS One. 2013;8(7):e68428. doi: 10.1371/journal.pone.0068428.
  113. Serra R, Ielapi N, Barbetta A et al. Novel biomarkers for cardiovascular risk. Biomark Med. 2018;12(9):1015-1024. doi: 10.2217/bmm-2018- 0056.
  114. Singh A, Chan DCS, Greenwood JP et al. Symptom onset in aortic stenosis: relation to sex differences in left ventricular remodeling. JACC Cardiovasc Imaging. 2017 Dec 8. pii: S1936-878X(17)30987-7. doi: 10.1016/j.jcmg.2017.09.019.
  115. Stamova B, Ander BP, Jickling G et al. The intracerebral hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes. J Cereb Blood Flow Metab. 2018 Apr 13:271678X18769513. doi: 10.1177/0271678X18769513.
  116. Staszewski J, Piusinska-Macoch R, Brodacki B et al. IL-6, PF-4, sCD40 L, and homocysteine are associated with the radiological progression of cerebral small-vessel disease: a 2-year follow-up study. Clin Interv Aging. 2018;13:1135-1141. doi: 10.2147/CIA.S166773.
  117. Stenemo M, Nowak C, Byberg L et al. Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail. 2018;20(1):55-62. doi: 10.1002/ejhf.980.
  118. Stewart LK, Nordenholz KE, Courtney M et al. Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. Blood Coagul Fibrinolysis. 2017;28(8):675-680. doi: 10.1097/ MBC.0000000000000669.
  119. Stoner L, Lucero AA, Palmer BR et al. Inflammatory biomarkers for predicting cardiovascular disease. Clin Biochem. 2013;46(15):1353-1371. doi: 10.1016/j.clinbiochem.2013.05.070.
  120. Subirana I, Fito M, Diaz O et al. Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism. Sci Rep. 2018;8(1):3191. doi: 10.1038/s41598-018-21482-y.
  121. Sun R, Wang L, Guan C et al. Carotid atherosclerotic plaque features in patients with acute ischemic stroke. World Neurosurg. 2018;112:e223-e228. doi: 10.1016/j.wneu.2018.01.026.
  122. Szabo P, Lantos J, Nagy L et al. l-Arginine pathway metabolites predict need for intra-operative shunt during carotid endarterectomy. Eur J Vasc Endovasc Surg. 2016;52(6):721-728. doi: 10.1016/j. ejvs.2016.10.008.
  123. Szük T, Fejes Z, Debreceni IB et al. Integrity(®) bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience(®) everolimus-eluting stents in stable angina patients. Platelets. 2016;27(5):410-419. doi: 10.3109/09537104.2015.1112368.
  124. Takawale A, Zhang P, Patel VB, et al. Tissue inhibitor of matrix metal-loproteinase-1 promotes myocardial fibrosis by mediating CD63-inte-grin ß1 interaction. Hypertension. 2017;69(6):1092-1103. doi: 10.1161/ HYPERTENSIONAHA.117.09045.
  125. Tamang HK, Timilsina U, Singh KP. ApoB/Apo A-I ratio is statistically a better predictor of cardiovascular disease (CVD) than conventional lipid profile: a study from Kathmandu Valley, Nepal. J Clin Diagn Res. 2014;8(2):34-36. doi: 10.7860/JCDR/2014/7588.4000.
  126. Teringova E, Tousek P. Apoptosis in ischemic heart disease. J Transl Med. 2017;15(1):87. doi: 10.1186/s12967-017-1191-y.
  127. Tin A, Astor BC, Boerwinkle E et al. Genome-wide significant locus of beta-trace protein, a novel kidney function biomarker, identified in European and African Americans. Nephrol Dial Transplant. 2013;28(6):1497-1504. doi: 10.1093/ndt/gfs591.
  128. Tomaszewski M, Eales J, Denniff M et al. Renal mechanisms of association between fibroblast growth factor 1 and blood pressure. J Am Soc Nephrol. 2015;26(12):3151 -3160. doi: 10.1681/ ASN.2014121211.
  129. Tuegel C, Katz R, Alam M, et al. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. Am J Kidney Dis. 2018 Jun 1. pii: S0272-6386(18)30636-X. doi: 10.1053/j.ajkd.2018.03.025.
  130. Tufekci KU, Vurgun U, Yigitaslan O et al. Follow-up analysis of serum TNF-related apoptosis-inducing ligand protein and mRNA expression in peripheral blood mononuclear cells from patients with ischemic stroke. Front Neurol. 2018;9:102. doi: 10.3389/fneur.2018.00102.
  131. Van de Voorde J, Pauwels B, Boydens C, Decaluwґe K. Adipocytokines in relation to cardiovascular disease. Metab. Clin. Exp. 2013;62(11):1513-1521. doi: 10.1016/j.metabol.2013.06.004.
  132. Van Taunay JS, Albelda MT, Frias JC, Lipinski MJ. Biologics and Cardiovascular Disease. J Cardiovasc Pharmacol. 2018;72(2):77-85. doi: 10.1097/FJC.0000000000000595.
  133. Wang BJ, Liu J, Geng J, Zhang Q, Hu TT, Xu B. Association between three interleukin-10 gene polymorphisms and coronary artery disease risk: a meta-analysis. Int. J. Clin. Exp. Med.2015;8(10):17842-17855. PMID: 26770379.
  134. Wang X, Lian Y, Wen X et al. Expression of miR-126 and its potential function in coronary artery disease. Afr Health Sci. 2017;17(2):474-480. doi: 10.4314/ahs.v17i2.22.
  135. Wasiak S, Gilham D, Tsujikawa LM et al. Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). J Cardiovasc Transl Res. 2017;10(4):337-347. doi: 10.1007/s12265-017-9755-z.
  136. Weymann A, Sabashnikov A, Ali-Hasan-Al-Saegh S et al. Predictive role of coagulation, fibrinolytic, and endothelial markers in patients with atrial fibrillation, stroke, and thromboembolism: a meta-analysis, meta-regression, and systematic review. Med Sci Monit Basic Res. 2017;23:97-140. doi: 10.12659/MSMBR.902558.
  137. White CA, Ghazan-Shahi S, Adams MA. ß-Trace protein: a marker of GFR and other biological pathways. Am J Kidney Dis. 2015;65(1):131-146. doi: 10.1053/j.ajkd.2014.06.038.
  138. Wigren M, Rattik S, Hultman K et al. Decreased levels of stem cell factor in subjects with incident coronary events. J Intern Med. 2016;279(2):180-191. doi: 10.1111/joim.12443.
  139. Wildgruber M, Aschenbrenner T, Wendorff H et al. The “Intermediate” CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans. Sci Rep. 2016;6:39483. doi: 10.1038/srep39483.
  140. Willeit P., Thompson S.G., Agewall S. et al. Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROGIMT Collaboration // Eur. J. Prev. Cardiol. 2016;23(2):194-205. doi: 10.1177/2047487314560664.
  141. Williams SR, Hsu FC, Keene KL et al. Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke. Neurology. 2016;86(4):351 -359. doi: 10.1212/WNL.0000000000002319.
  142. Xu Y, Meng HL, Su YM et al. Serum YKL-40 is increased in patients with slow coronary flow. Coron Artery Dis. 2015;26(2):121-125. doi: 10.1097/ MCA.0000000000000191.
  143. Xuan Y, Wang L, Zhi H, Li X, Wei P. Association between 3 IL-10 gene polymorphisms and cardiovascular disease risk: systematic review with meta-analysis and trial sequential analysis. Medicine (Baltimore).2016;95(6):e2846. doi: 10.1097/MD.0000000000002846.
  144. Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628-651. doi: 10.1016/j.ca rdfail.2017.04.014.
  145. Zhao Q, Liu Z, Huang B, et al. PEDF improves cardiac function in rats subjected to myocardial ischemia/reperfusion injury by inhibiting ROS generation via PEDF-R. Int J Mol Med. 2018;41 (6):3243-3252. doi: 10.3892/ijmm.2018.3552.
  146. Zhou Z, Zhang J, Li X et al. Protein microarray analysis identifies key cytokines associated with malignant middle cerebral artery infarction. Brain Behav. 2017;7(8):e00746. doi: 10.1002/brb3.746.
  147. Zuniga MC, Tran TB, Baughman BD et al. A prospective evaluation of systemic biomarkers and cognitive function associated with carotid revascularization. Ann Surg. 2016;264(4):659-665. doi: 10.1097/ SLA.0000000000001853.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Physical and rehabilitation medicine, medical rehabilitation, 2020


 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».